

## ALCOHOL USE DISORDER OUTPATIENT PRESCRIPTION

Weight (kg)

R				
Date (dd/mm/yyyy)Allergies				
First-line treatment				
<ul> <li>naltrexone 25 mg PO DAILY × 3 days, then naltrexone 50 mg PO DAILY</li> <li>Contraindicated if active opioid use disorder OR prescription opioids for pain, acute hepatitis, liver enzymes greater than 5 times normal, or liver failure</li> </ul>			Quantity	# Refill
<ul> <li>acamprosate 666 mg PO TID</li> <li>For patients with CrCl greater than 50 mL/min</li> </ul>			Quantity	# Refill
<ul> <li>acamprosate 333 mg PO TID</li> <li>For patients with CrCl 30 to 50 mL/min.</li> <li>Naltrexone is recommended first-line agent if renal impairment.</li> </ul>			Quantity	# Refill
Second-line treatment				
<ul> <li>gabapentin 300 mg PO TID × 24 hours, then if well tolerated increase to 600 mg PO TID</li> <li>Use caution if renal impairment, dose reductions required</li> </ul>			Quantity	# Refill
<ul> <li>topiramate 25 mg PO QHS × 7 days, then increase to 25 mg PO BID × 7 days, then increase to 50 mg PO BID</li> <li>Use caution if renal impairment, dose reductions required</li> </ul>			Quantity	# Refill
□ Other			Quantity	☐ # Refill
Withdrawal managemer	nt if low risk o	f complicated withdrawal		
<ul> <li>gabapentin 300 to 600 mg PO QID PRN withdrawal symptoms</li> <li>Use caution if renal impairment, dose reductions required</li> </ul>			Quantity	# Refill
Date (dd/mm/yyyy)	Time (24 hour)	Physician Signature		Printed name or College ID#
	Time (27 nour)	Trysisian olynataio		Times name of college ID#

**805003** Jun 15**-**23 Page 1 of 1

Patient consents to try Pharmacologic Treatment for their AUD



